Ampersand Biomedicines
Andrew Kinloch is an accomplished scientist with extensive experience in immunology and platform innovation. Currently serving as Principal Scientist at both Flagship Pioneering and Ampersand Biomedicines since August 2021, Andrew previously held a position as Senior Scientist at Eutropics, where leadership in assay development and next-generation platform initiatives was pivotal for advancing therapies in leukemia and solid tissue cancers. Andrew's career began with a long tenure at the University of Chicago, contributing to the characterization of patient-derived monoclonal antibodies during chronic inflammatory diseases. The academic journey includes a PhD in Immunology from Imperial College London, alongside research roles at prestigious institutions such as Harvard University and the University of Cambridge.
This person is not in any offices
Ampersand Biomedicines
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.